Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.
作者信息
Liu Yujie, Xie Jianhua, Li Zhuxiang, Mei Xiong, Cao Di, Li Shengfeng, Engle Linda, Liu Suli, Ebbers Hans C, Liu Cuihua
机构信息
Bio-Thera Solutions, Ltd, Floor 5, Building A6, 11 Kai-Yuan Blvd, Huangpu District, Guangzhou, 510530, Guangdong, China.
Biogen Inc, Cambridge, MA, USA.
出版信息
BioDrugs. 2024 Sep;38(5):725. doi: 10.1007/s40259-024-00672-3.
Abstract
摘要
相似文献
1
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.对《生物类似药BAT1806/BIIB800与对照托珠单抗的物理化学及功能相似性证明》的勘误
BioDrugs. 2024 Sep;38(5):725. doi: 10.1007/s40259-024-00672-3.
2
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.生物类似药 BAT1806/BIIB800 与参比药物托珠单抗的理化性质和功能相似性的验证。
BioDrugs. 2024 Jul;38(4):571-588. doi: 10.1007/s40259-024-00662-5. Epub 2024 Jun 18.
3
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.与甲氨蝶呤治疗应答不足的中重度类风湿关节炎患者比较托珠单抗生物类似药 BAT1806/ BIIB800 与参照药托珠单抗：一项 3 期、随机、多中心、双盲、阳性药物对照的临床试验。
Lancet Rheumatol. 2024 Jan;6(1):e40-e50. doi: 10.1016/S2665-9913(23)00237-0.
4
Comparative Structure Activity Relationship Characterization of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.生物类似药BAT1806/BIIB800与对照托珠单抗的比较结构活性关系表征
BioDrugs. 2025 Mar;39(2):307-320. doi: 10.1007/s40259-024-00698-7. Epub 2025 Mar 6.
5
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).一项 3 期、随机、双盲、阳性对照临床试验，旨在比较 BAT1806/BIIB800（一种托珠单抗生物类似药）与托珠单抗参比制剂在对甲氨蝶呤应答不足的中重度类风湿关节炎患者中的疗效：治疗期 2 分析（第 24 周至第 48 周）。
Arthritis Res Ther. 2024 Sep 7;26(1):157. doi: 10.1186/s13075-024-03375-w.
6
A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men.一项比较拟用生物类似药BAT1806与对照药托珠单抗在健康中国男性中的耐受性、免疫原性和药代动力学的I期临床研究。
Front Pharmacol. 2021 Jan 25;11:609522. doi: 10.3389/fphar.2020.609522. eCollection 2020.
7
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product.托珠单抗生物类似药静脉注射用BAT1806与其参比产品的免疫原性比较
Rheumatol Ther. 2025 Jun;12(3):529-546. doi: 10.1007/s40744-025-00760-y. Epub 2025 Apr 8.
8
A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra) in Chinese healthy subjects.一项比较潜在生物类似药托珠单抗（QX003S）与参比制剂（雅美罗）在健康中国受试者中的药代动力学的随机 I 期临床试验。
Ann Med. 2021 Dec;53(1):375-383. doi: 10.1080/07853890.2021.1887925.
9
Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.拟生物类似药托珠单抗的物理化学和生物学特性
Biomed Res Int. 2017;2017:4926168. doi: 10.1155/2017/4926168. Epub 2017 Mar 2.
10
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.一种拟用托珠单抗生物类似药 MSB11456 的药代动力学和药效学与美国许可和欧盟批准产品的比较：一项随机、双盲试验。
Expert Rev Clin Immunol. 2022 May;18(5):533-543. doi: 10.1080/1744666X.2022.2060204. Epub 2022 Apr 10.
Zotero 插件